Translational Controversies: Utility of MRD and ctDNA in Breast Cancer

Moderator

David Cescon, Toronto, ON, Canada

Presentation numberCT2-01

Is MRD Ready for Prime Time?

Nick Turner

Presentation numberCT2-02

ctDNA Guided Endpoints in Metastatic Disease

Jo Chien, UCSF, San Francisco, CA

Presentation numberCT2-03

Endpoints in Modern Clinical Trials

Yu Shyr

Presentation numberCT2-04

Navigating MRD Testing: Partnering with Patients to Optimize Care

Patricia A Spears